ArticleJournal of translational medicine2026
Triple-remodeling of tumor microenvironment through hyaluronidase-assisted folate-targeted lipid nanoparticle-mediated siVEGF/siPD-L1 for enhanced tumor immunotherapy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatially organized regulated cell death-immune coupling in solid tumors: integrating spatial omics with actionable regulated cell death biology.Molecular cancer · 2026Review
- From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery.Materials today. Bio · 2026Review
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn tumor therapy, traditional single-treatment methods often fail to achieve ideal results because of problems like the complex tumor microenvironment, immune escape mechanisms, and abnormal blood vessel formation. Although there are now several combined treatment strategies, challenges remain in precise drug delivery and achieving multi - target synergistic effects.
methodsThis study aims to create an efficient combined anti-tumor lipid nanoparticle (LNP) delivery system. We added DMG-PEG2000-FA to the four-component lipid nanoparticle system and used microfluidic technology to prepare FA-LNP with tumor-targeting groups. These delivery systems were loaded with the pSpam-1 gene, siVEGF, and siPD-L1 separately.
resultsThe pSpam-1 gene can express hyaluronidase in tumor tissues, degrade the tumor extracellular matrix, and boost the infiltration of nanodrugs and immune cells into tumor tissues. siVEGF exerts an anti-angiogenic effect, cutting off tumor nutrient supply. siPD-L1 achieves immune checkpoint blockade, activating the body’s immune system. Experimental show that this FA-LNP achieves effective multi-target synergy, greatly inhibiting tumor growth and achieving highly efficient combined anti-tumor effects both in vitro and in vivo. Further immune mechanism research reveals it can regulate immune cell function and distribution in the tumor microenvironment.
conclusionsCombining extracellular matrix degradation, anti-angiogenesis, and immune checkpoint blockade led to a highly efficient synergistic anti-tumor effect. The in-depth immune mechanism research offers valuable insights into how these strategies interact and contribute to the overall anti-tumor response. This FA-LNP delivery system is expected to offer a safer and more effective tumor therapy strategy and promote personalized tumor treatment development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.